peptideInjectableNot FDA-approvedResearch chemicalNot permitted in 503A compounding (FDA Category 2)Prohibited in sport (WADA S0)
BPC-157Benefits, Dosage & Interactions
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids, derived from a larger protein found in stomach acid. Research on BPC-157 focuses on tissue recovery. BPC-157 is administered by injection rather than orally. BPC-157 is a controlled substance in some jurisdictions.
How much BPC-157 do people take?
No published human dose-finding trial exists. Rodent studies consistently used 10 ng/kg to 10 µg/kg per administration. Route reported: Intraperitoneal, intragastric or topical in the published animal work; no validated human route. Frequency reported: Once daily for the treatment period in most rodent protocols. These are amounts documented in the cited studies and labels for BPC-157 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
<30 min (rats, beagle dogs, intravenous — no human PK study)
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- No published human dose-finding trial exists. Rodent studies consistently used 10 ng/kg to 10 µg/kg per administration[1][2][3][4]
- Route studied
- Intraperitoneal, intragastric or topical in the published animal work; no validated human route[1][2][3][4]
Reported for BPC-157 in the cited sources. Published ranges are not dosing advice.
Mixing BPC-157: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, BPC-157 vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
BPC-157 compared with similar compounds
| Attribute | BPC-157 | TB-500 | BPC-157 Arginate |
|---|---|---|---|
| Class | Synthetic pentadecapeptide (gastric juice derived) | Synthetic thymosin beta-4 fragment | Arginate salt of BPC-157 |
| Route | Injectable or oral in animal studies | Injectable | Oral or injectable |
| Half-life | Not established in humans | Not established in humans | Not established in humans |
| Evidence grade | Preclinical | Preclinical | Insufficient |
| Oral stability | Reported stable in gastric juice | Not orally stable | Marketed for improved oral stability; unpublished |
| Typical published cycle | 7–28 days in animal models | 4–6 weeks in animal models | No published protocol |
| Main studied use | Soft-tissue and gastrointestinal healing | Cell migration, angiogenesis, wound repair | Same targets as BPC-157, without separate published data |
References & evidence
Documents the BPC-157 entry is written from. Each number matches an inline marker above.
- [1]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tractSikiric P, Seiwerth S, Rucman R, et al. · Current Pharmaceutical Design · 2011 · Peer-reviewed · PMID 21548867
- [2]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationChang CH, Tsai WC, Lin MS, Hsu YH, Pang JS · Journal of Applied Physiology · 2011 · Peer-reviewed · PMID 21030672
- [3]BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healingSeiwerth S, Rucman R, Turkovic B, et al. · Current Pharmaceutical Design · 2018 · Peer-reviewed · PMID 29998800
- [4]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healingGwyer D, Wragg NM, Wilson SL · Cell and Tissue Research · 2019 · Peer-reviewed · PMID 30915550
- [5]BPC-157 — FDA review of bulk drug substances nominated for use in compounding under section 503A (Category 2)U.S. Food and Drug Administration · 2023 · Regulatory
- [6]BPC-157 — PubChem compound summaryNIH National Library of Medicine · Reference database
References & Evidence
Sources on this page that document BPC-157 dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is BPC-157 studied for?
What is BPC-157?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids, derived from a larger protein found in stomach acid. It has been the subject of research for its potential role in tissue repair and regeneration across various organ systems, including the musculoskeletal, gastrointestinal, and nervous systems. While it has garnered interest in the scientific community and among individuals seeking recovery from injuries, BPC-157 is primarily an experimental compound. It is **not approved by the Food and Drug Administration (FDA) for human use** and is typically investigated in preclinical models or in the context of research studies. Its classification as a research chemical means that its availability and use are often unregulated, and comprehensive clinical trials establishing its efficacy and safety in humans are still limited. (Source: PubChem)
What does the research say about BPC-157?
Tap a section to expand.
The precise mechanisms by which BPC-157 exerts its effects are still under investigation, but several pathways have been proposed based on preclinical research. One key mechanism involves its role in angiogenesis, the formation of new blood vessels. BPC-157 appears to promote the migration and survival of endothelial cells, which are crucial for this process, thereby enhancing blood flow to injured tissues. This improved blood supply can facilitate nutrient and oxygen delivery, accelerating healing. (Source: PubChem)
Another proposed mechanism is its interaction with various growth factors and signaling pathways. Research suggests that BPC-157 may modulate the activity of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF), all of which are important for tissue repair and regeneration. It may also influence the expression of specific genes involved in extracellular matrix remodeling and cell proliferation. (Source: PubChem)
Furthermore, BPC-157 has been observed to have anti-inflammatory and protective effects. It may reduce the production of pro-inflammatory cytokines and protect cells from oxidative stress, contributing to an environment conducive to healing. Its gastroprotective properties, from which it derives some of its name, are thought to involve strengthening the mucosal barrier and improving blood flow to the gastrointestinal tract. (Source: Examine.com)
Source for this section: Sources for How does BPC-157 work?: Jumps to this entry in the sources and references list at the end of the page.
Research into the benefits of BPC-157 has primarily focused on its potential for tissue repair and regeneration across different body systems. These effects have been observed mainly in preclinical studies, largely in rodents, and clinical evidence in humans is limited.
* **Musculoskeletal Healing:** Preclinical studies suggest that BPC-157 may accelerate the healing of various musculoskeletal injuries, including muscle tears, tendon injuries (such as Achilles tendon and quadriceps tendon ruptures), and ligament damage. It appears to promote tendon-to-bone healing and improve the biomechanical strength of repaired tissues. (Source: Examine.com)
* **Gastrointestinal Protection and Repair:** BPC-157 has shown significant gastroprotective properties. It may aid in the healing of gastric ulcers, esophageal damage, and other forms of intestinal injury. Its protective effects extend to mitigating damage caused by various stressors, including NSAID-induced ulcers. (Source: Examine.com)
* **Nervous System Recovery:** Some research indicates potential neuroprotective properties, with studies exploring its role in nerve regeneration after injury and its possible effects on brain function after traumatic brain injury or stroke. (Source: PubChem)
* **Anti-inflammatory and Pain-reducing Effects:** BPC-157 may exhibit anti-inflammatory actions, which could contribute to pain reduction and improved recovery from injury. (Source: Examine.com)
It is crucial to reiterate that these potential benefits are largely derived from animal models, and human clinical data are scarce. The safety and efficacy of BPC-157 for these uses in humans have not been established by regulatory bodies like the FDA.
Evidence for BPC-157's effects is primarily derived from preclinical studies, predominantly using rodent models. A significant body of research exists in peer-reviewed scientific literature detailing its impact on various tissue types and injury models. For instance, studies published in journals such as the *Journal of Physiology and Pharmacology* have explored its role in tendon and ligament healing. Other papers have documented its gastroprotective effects and its influence on gastric ulcer healing. (Source: PubChem, Examine.com)
While these preclinical findings are promising, they do not directly translate to human efficacy or safety. There is a notable lack of large-scale, placebo-controlled human clinical trials, which are considered the gold standard for establishing a compound's therapeutic value. Regulatory agencies like the FDA in the United States have not approved BPC-157 for any medical use in humans, classifying it as a research chemical. This means that extensive human safety and dosing profiles are not yet established. The current evidence base is sufficient to generate hypotheses for future clinical investigation but is insufficient to recommend its use for therapeutic purposes in humans outside of a supervised research setting. (Source: NIH ODS)
Due to the limited human clinical trial data for BPC-157, a comprehensive list of potential side effects in humans is not well-established. Most information is extrapolated from animal studies or anecdotal reports, which are not reliable indicators of safety for the general population. As an experimental compound, the full spectrum of potential adverse reactions, their frequency, and severity remain largely unknown.
Potential, but unconfirmed, side effects based on limited reporting or theoretical considerations might include:
* **Injection site reactions:** As BPC-157 is often administered via injection, localized pain, redness, swelling, or irritation at the injection site are possible.
* **Gastrointestinal disturbances:** While BPC-157 is studied for gastroprotection, individual sensitivities could theoretically lead to issues.
* **Headache or dizziness:** These are generalized symptoms that can occur with various compounds.
* **Changes in blood pressure:** Some compounds can influence cardiovascular parameters.
It is imperative to understand that this is not an exhaustive list, and unforeseen side effects may occur. Given the lack of robust human safety data, users should exercise extreme caution. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
BPC-157 is a research compound and is **not approved for human use by the FDA or other major regulatory bodies**. Therefore, there are significant warnings and precautions associated with its use.
* **Lack of Regulatory Oversight:** As an unapproved compound, BPC-157 products may not be subject to quality control, purity, or dosage accuracy regulations. This means that products sold as BPC-157 may contain impurities, incorrect dosages, or altogether different substances, posing significant health risks.
* **Unknown Long-Term Safety:** The long-term effects of BPC-157 in humans are entirely unknown. There is no data on potential carcinogenicity, reproductive toxicity, or other chronic adverse effects.
* **Potential for Unforeseen Interactions:** Without comprehensive clinical trials, the potential for interactions with prescription medications, over-the-counter drugs, supplements, or pre-existing health conditions is unknown.
* **Immunogenicity:** As a peptide, there is a theoretical risk of immune reactions, though there is no significant data available on this for BPC-157 in humans.
* **Not for Self-Administration:** Given its experimental status, BPC-157 should not be self-administered. Any use should only occur under the strict supervision of a licensed clinician in a controlled research setting.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the experimental nature of BPC-157 and the severe lack of comprehensive human safety data, absolute contraindications are not definitively established. However, based on general medical principles and the unknown risks, BPC-157 is generally contraindicated in certain populations or conditions.
* **Pregnancy and Breastfeeding:** There is no safety data for BPC-157 in pregnant or breastfeeding individuals. Its use is strongly advised against due to potential unknown risks to the fetus or infant.
* **Children and Adolescents:** The safety and effects of BPC-157 in pediatric populations are entirely unknown. Its use is contraindicated in individuals under the age of 18.
* **Cancer or History of Cancer:** Given BPC-157's proposed role in cell proliferation and angiogenesis, there is a theoretical concern that it could potentially promote cancer growth or recurrence. Its use is generally contraindicated in individuals with active cancer or a history of cancer until more is known about these interactions.
* **Individuals on Immunosuppressants or with Autoimmune Conditions:** The potential effects of BPC-157 on the immune system are not fully understood, making its use potentially risky for individuals with autoimmune diseases or those on immunosuppressive therapy.
* **Individuals with Undiagnosed Conditions:** Without a clear medical diagnosis, introducing an experimental compound like BPC-157 is highly inadvisable due to the potential for masking symptoms or exacerbating underlying conditions.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the limited research on BPC-157 in human subjects, there is insufficient data to provide a comprehensive list of compounds or substances that should not be mixed with it. The potential for drug-drug interactions, drug-supplement interactions, and interactions with various food or lifestyle factors is largely unexplored. As a general principle for any experimental or unapproved compound:
* **Prescription Medications:** Extreme caution should be exercised if considering BPC-157 alongside any prescription medication. This includes, but is not limited to, blood thinners, immunosuppressants, medications for chronic conditions, or any drug with a narrow therapeutic index. BPC-157's influence on inflammation, blood vessel growth, and cell proliferation could theoretically alter the effects or metabolism of other drugs.
* **Other Peptides or Supplements:** Combining BPC-157 with other experimental peptides, growth factors, or supplements that also influence tissue repair, inflammation, or hormonal pathways could lead to synergistic, antagonistic, or unpredictable effects. The safety and efficacy of such combinations are unknown.
* **Alcohol and Recreational Substances:** There is no data on how BPC-157 interacts with alcohol or recreational substances. Such combinations could lead to unpredictable and potentially harmful outcomes.
* **Herbal Remedies:** Similar to supplements, the interaction of BPC-157 with various herbal remedies is unknown and could pose risks.
Given the lack of human safety and interaction data, it is safest to assume that BPC-157 could potentially interact negatively with a wide range of substances. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for BPC-157 administration in research settings can vary, and precise recommendations for human use are not established due to its experimental status. In animal studies, administration often occurs around the time of injury or for a sustained period during the healing process.
* **Frequency:** In preclinical research, BPC-157 has been administered daily or multiple times a day, depending on the specific study design and injury model.
* **Duration:** The duration of administration has ranged from a few days to several weeks, coinciding with observed healing phases in the respective animal models.
* **Regarding food:** Animal studies have not typically indicated specific interactions with food, suggesting it can be administered either with or without food. However, this may not directly translate to human physiology.
For human use, in the context of user-directed or off-label application, dose and timing must be set by a licensed clinician. Without approved clinical guidelines, any timing recommendations are anecdotal and not supported by regulatory bodies. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should you take BPC-157?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about BPC-157 is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with BPC-157?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about BPC-157
No, BPC-157 is not approved by the Food and Drug Administration (FDA) for human use. It is considered an experimental research compound.
Primarily based on preclinical (animal) research, BPC-157 is studied for its potential in accelerating the healing of various tissues, including muscle, tendons, ligaments, and gastrointestinal tissues. It may also have anti-inflammatory and neuroprotective effects.
Due to very limited human clinical data, a comprehensive list of side effects in humans is not established. Potential, but unconfirmed, side effects might include injection site reactions or general discomfort. The full safety profile in humans is unknown.
BPC-157's classification as "controlled" typically refers to its status as a research chemical not intended for general human use, meaning its sale and distribution are restricted. However, it is not scheduled under the Controlled Substances Act in the same manner as narcotics, but rather regulated through research chemical vendors or compounding pharmacies under specific conditions.
The name BPC-157 (Body Protection Compound-157) reflects its origin from a larger protective protein found in human stomach acid, which plays a role in maintaining the integrity of the gastrointestinal lining and promoting healing.
BPC-157 is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers BPC-157 with no sign-up.
BPC-157 is administered by injection, so the measured volume — not a tablet count — is the unit that matters. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a peptide like BPC-157 with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against BPC-157: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for BPC-157 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of BPC-157 depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like BPC-157 the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
No published human dose-finding trial exists. Rodent studies consistently used 10 ng/kg to 10 µg/kg per administration. Route reported: Intraperitoneal, intragastric or topical in the published animal work; no validated human route. Frequency reported: Once daily for the treatment period in most rodent protocols. These are amounts documented in the cited studies and labels for BPC-157 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 9941957(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/9941957
Verify at
Publisher search links for BPC-157. These are places to check the information — they are not citations, so they are not numbered.
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on BPC-157?
Plain-text summary, safe to quote verbatim:
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids, derived from a larger protein found in stomach acid. Research on BPC-157 focuses on tissue recovery. BPC-157 is administered by injection rather than orally. BPC-157 is a controlled substance in some jurisdictions.
Source: DoseRoutine — https://doseroutine.com/library/bpc-157
BPC-157 cheat sheet
DoseRoutine cheat sheet · Peptide
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids, derived from a larger protein found in stomach acid.
Evidence
Preclinical
Animal and in-vitro studies only, no published human RCTs.
Studied range
No published human dose-finding trial exists. Rodent studies consistently used 10 ng/kg to 10 µg/kg per administration
Route
Intraperitoneal, intragastric or topical in the published animal work; no validated human route
Frequency studied
Once daily for the treatment period in most rodent protocols
Half-life
Not established in humans; the peptide is reported as stable in human gastric juice, with no published human pharmacokinetic profile
Storage
Lyophilized peptide stored refrigerated and protected from light in the source literature
Not FDA-approvedResearch chemicalNot permitted in 503A compounding (FDA Category 2)Prohibited in sport (WADA S0)Recovery
Key references
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (2011)
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (2011)
- BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing (2018)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/bpc-157
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). BPC-157 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/bpc-157
What compounds are similar to BPC-157?
Others in the peptide category or studied for the same goals.
Which goals is BPC-157 used for?
Other compounds studied for the same benefits as BPC-157.
Continue exploring
See every compound DoseRoutine catalogs for these goals.